CPhI Announces 2014 Expert Panel and Report - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

CPhI Announces 2014 Expert Panel and Report



CPhI Worldwide has announced its confirmed expert industry panel members for 2014. This year’s panel sees the return of ten thought leaders with the addition of three new members, covering the entire pharmaceutical supply chain from R&D through to finished products, regulatory requirements, and economic implications.

Additionally, this year panel members are using their market insights and analysis year-round in the CPhI Pharma Insights series, which covers individual topics and developments across the industry including the released R&D, manufacturing, and Turkey reports, with a US report due out soon.

The new panel members are all from the contract manufacturing arena, including: Alan Armonstrong, CEO and Douglas Cookson, VP corporate marketing from Almac; Hendrik Baumann, CEO of Arevipharma; and Lukas Utiger, president of fine chemicals and integrated offering at DSM. Collectively they provide a global overview of outsourcing, with Almac and Arevipharma focusing on the international market from a European stance and DSM from a US perspective.

The returning members include Girish Malhotra, Sam Venugopal, Piramal’s Vijay Shah, Hedley Rees, Prabir Basu, Dilip Shah, Emil Ciurczak, and William Botha.

The 2014 annual report features a collection of in-depth essays from each panel member, with experts predicting how the industry will look and operate in the future from both an economic and practical perspective.

Source: CPhI Worldwide

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here